1. Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse events
- Author
-
Marwa Bachir, Lorenzo Guglielmetti, Simone Tunesi, Typhaine Billard-Pomares, Sheila Chiesi, Jérémy Jaffré, Hugo Langris, Valérie Pourcher, Frédéric Schramm, Nadine Lemaître, Jérôme Robert, O. Bouchaud, T. Billard-Pomares, E. Carbonnelle, F. Mechaï, H. Nunes, M. Pellan, A.-S. Morin, C. Dumesnil, J. Dumoulin, A.-L. Roux, M. Jachym, D. le Du, D. Marigot-Outtandy, S. Abgrall, V. Chambrin, C. Guillet, B. Fantin, A. Galy, J.-W. Decousser, J.D. Lelièvre, S. Gallien, B. Nebbad-Lechani, L. Deconinck, S. Bulifon, N. Fortineau, B. Wyplosz, F. Cohen, N. Lemaitre, B. Crestani, N. Grall, C. Pierre-Audigier, C. Rioux, Y. Yazdanpanah, C. Le Jeunne, P. Morand, N. Roche, J. Pavie, P. Loulergue, V. Delcey, E. Lecorché, A.-L. Munier, F. Mougari, P. Sellier, E. Bille, A. Ferroni, R. Guéry, A. Hummel, J. Lourenco, A. Aubry, I. Bonnet, E. Caumes, C. Londner, F. Morel, K. Lacombe, V. Lalande, J.-L. Meynard, N. Veziris, N. De Castro, B. Denis, M. Lafaurie, J.-M. Molina, A. Canestri, L. Lassel, G. Pialoux, C. Verdet, A.-L. Nardi, M. Gominet, and E. Catherinot
- Subjects
Tuberculosis ,Isoniazid ,Drug resistance ,Risk factors ,Epidemiology ,Infectious and parasitic diseases ,RC109-216 - Abstract
Objectives: Isoniazid-monoresistant tuberculosis (HR-TB) is the most prevalent form of drug-resistant TB worldwide and in France and is associated with poorer treatment outcomes compared with drug-susceptible TB (DS-TB). The objective of this study was to determine the characteristics of HR-TB patients in France and to compare outcomes and safety of treatment for HR-TB and DS-TB. Methods: We performed a case-control multicenter study to identify risk factors associated with HR-TB and compare treatment outcomes and safety between HR-TB patients and DS-TB patients. Results: Characteristics of 99 HR-TB patients diagnosed and treated in the university hospitals of Paris, Lille, Caen and Strasbourg were compared with 99 DS-TB patients. Female sex (OR = 2.2; 1.0–4.7), birth in the West-Pacific World Health Organization region (OR = 4.6; 1.1–18.7) and resistance to streptomycin (OR = 77.5; 10.1–594.4) were found to be independently associated with HR-TB. Rates of treatment success did not differ significantly between HR-TB and DS-TB. Conclusions: Factors associated with HR-TB are not significant enough to efficiently screen TB patients at risk of HR-TB. The systematic implementation of rapid molecular testing on clinical samples remains the only effective way to make the early diagnosis of HR-TB and adapt treatment.
- Published
- 2021
- Full Text
- View/download PDF